AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference

ALISO VIEJO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that the Company will present at the UBS 2010 Global Life Sciences Conference on Wednesday, September 22nd at 3:30 p.m. Eastern time (12:30 p.m. Pacific time) at the Grand Hyatt New York.  The UBS Global Life Sciences Conference provides industry leaders in the life sciences sector with the opportunity to present to top institutional investors.  

A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the UBS Global Life Sciences Conference will be available on the Company's website for 30 days.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.  As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.  For more information about AVANIR, please visit www.avanir.com.  

SOURCE AVANIR Pharmaceuticals, Inc.

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.